Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
Study sponsor: Omeros Corporation
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-01-12Actual
Enrollment · participants360Actual
Source updated2025-12-09Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.